Data Composite

Drug Recalls

Recent drug recall reports from the FDA (US) and Health Canada, newest first. Each entry links to the full record -- product description, reason for recall, and severity classification -- refreshed daily.

Wells Pharma of Houston LLC

US Class II Ongoing · initiated 2026-04-01

cGMP deviations.

Wells Pharma of Houston LLC

US Class II Ongoing · initiated 2026-04-01

cGMP deviations.

Joint pain relief capsule; Magnesium bisglycinate Capsules; Maca capsules

Canada Type III Ongoing · initiated 2026-04-01

Packaging. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns…

Health First Vitamine E capsule

Canada Type III Ongoing · initiated 2026-04-01

Product quality. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health co…

Avantor Performance Materials LLC

US Class III Ongoing · initiated 2026-03-31

Subpotent drug

LUXA-D

Canada Type III Ongoing · initiated 2026-03-31

Product safety. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health con…

Auro-Canagliflozin

Canada Type III Ongoing · initiated 2026-03-31

Product safety. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health con…

pms-MOXIFLOXACIN HCL 0.5% LIQ 3 mL

Canada Type II Ongoing · initiated 2026-03-30

Product quality. Verify if your product is affected. Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health c…

Appco Pharma LLC

US Class II Ongoing · initiated 2026-03-27

cGMP deviation: detection of Nitrosamine Drug Substance-Related Impurities, N-nitroso-prazosin impurity C (NNP) above acceptable limits.

Appco Pharma LLC

US Class II Ongoing · initiated 2026-03-27

cGMP deviation: detection of Nitrosamine Drug Substance-Related Impurities, N-nitroso-prazosin impurity C (NNP) above acceptable limits.

Appco Pharma LLC

US Class II Ongoing · initiated 2026-03-27

cGMP deviation: detection of Nitrosamine Drug Substance-Related Impurities, N-nitroso-prazosin impurity C (NNP) above acceptable limits.

Hetero Labs Limited (Unit V)

US Class II Ongoing · initiated 2026-03-26

Discoloration: Firm received five (5) complaints stating that, "Tablets discolored darker than normal and have lighter-colored spots."

HIZENTRA

Canada Type II Ongoing · initiated 2026-03-26

Product safety. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product, or for any health concer…

Preferred Pharmaceuticals, Inc.

US Class II Ongoing · initiated 2026-03-25

Lack of Assurance of Sterility

SUN PHARMACEUTICAL INDUSTRIES INC

US Class II Ongoing · initiated 2026-03-25

Failed Viscosity Specifications: Out of Specification results, above the specification limit, in viscosity, noted during stability testing.

SUN PHARMACEUTICAL INDUSTRIES INC

US Class II Ongoing · initiated 2026-03-25

Failed Viscosity Specifications: Out of Specification results, above the specification limit, in viscosity, noted during stability testing.

SUN PHARMACEUTICAL INDUSTRIES INC

US Class II Ongoing · initiated 2026-03-25

Failed Viscosity Specifications: Out of Specification results, above the specification limit, in viscosity, noted during stability testing.

GE Healthcare Ireland Limited

US Class II Ongoing · initiated 2026-03-24

Presence of particulate matter

GE Healthcare Ireland Limited

US Class II Ongoing · initiated 2026-03-24

Presence of particulate matter

The Harvard Drug Group LLC

US Class II Ongoing · initiated 2026-03-24

Failed Dissolution Specifications

Fagron Compounding Services

US Class II Ongoing · initiated 2026-03-20

Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port

Fagron Compounding Services

US Class II Ongoing · initiated 2026-03-20

Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port

Fagron Compounding Services

US Class II Ongoing · initiated 2026-03-20

Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port

Fagron Compounding Services

US Class II Ongoing · initiated 2026-03-20

Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port

Fagron Compounding Services

US Class II Ongoing · initiated 2026-03-20

Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port